Action 1530 3SBIO INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues 3SBio Inc.

Actions

1530

KYG8875G1029

Marché Fermé - Hong Kong S.E.
Autres places de cotation
 10:08:17 17/05/2024 		Varia. 5j. Varia. 1 janv.
6,35 HKD -1,85 % Graphique intraday de 3SBio Inc. -5,79 % -15,56 %
22/04 3Sbio Inc. annonce des changements au sein de sa direction CI
12/04 3SBio Inc. approuve la thrombopoïétine humaine recombinante injectable (TPIAO) pour le traitement du PTI chez l'enfant CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
3Sbio Inc. Announces Management Changes
3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia
3SBio Inc. Approves Recombinant Human Thrombopoietin Injection for Pediatric ITP Indication
3SBio Inc. commences an Equity Buyback for 243,892,041 shares, representing 10% of its issued share capital, under the authorization approved on June 20, 2023.
3SBio's 2023 Profit Falls 19%, EPS Misses Estimates
3SBio Inc. Proposes Final Dividend for the Year Ended 31 December 2023, Payable on August 05, 2024
3SBio Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
China's NMPA Gives 3SBio Permission to Sell Anti-Dandruff Product
Mandi Foam of 3SBio Inc. Approves for Market Launch
Venus Medtech Names Former 3SBio Finance Chief as CFO
3SBio Secures Exclusive License to CStone's Anti-Tumor Drug in China
3SBio's H1 Attributable Profit Rises, Beats EPS Estimates
3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced
3SBio : 2023 Interim Results Presentation
3SBio Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
3SBio Hires Former JPMorgan Exec as CFO
3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer
3SBio Rolls Out Pruritus Medication in China
3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market
3SBio Inc.'s Equity Buyback announced on July 15, 2022, has expired.
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 1530
  4. Actualités 3SBio Inc.
  5. Autres langues